{"id":"NCT00641667","sponsor":"Janssen Pharmaceutical K.K.","briefTitle":"An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain","officialTitle":"A Phase III Study of JNS020QD in Cancer Pain Patients - Evaluation of the Efficacy and Safety of JNS020QD Switched From Opioid Analgesics","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2008-06","completion":"2008-06","firstPosted":"2008-03-24","resultsPosted":"2013-05-08","lastUpdate":"2013-06-07"},"enrollment":66,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pain","Cancer"],"interventions":[{"type":"DRUG","name":"Fentanyl","otherNames":["JNS020QD"]}],"arms":[{"label":"Fentanyl","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of fentanyl one-day transdermal patch (patch containing a drug that is put on the skin so the drug will enter the body through the skin) in participants switched from morphine preparations, oral oxycodone preparations, fentanyl citrate injection or fentanyl patch for cancer pain.","primaryOutcome":{"measure":"Percentage of Participants Achieving Pain Control","timeFrame":"Day 10 or early discontinuation (ED)","effectByArm":[{"arm":"Fentanyl","deltaMin":81.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":66},"commonTop":["Somnolence","Constipation","Nausea","Vomiting","Diarrhoea"]}}